News Releases

News Releases

Date Title
Dec 1, 2020 Sesen Bio Announces Partnership with Hikma Pharmaceuticals for the Commercialization of Vicineum™ in the Middle East and North Africa
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 1, 2020-- Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, and Hikma Pharmaceuticals , a multi-national pharmaceutical company and leading licensing partner in
Nov 9, 2020 Sesen Bio Reports Third Quarter 2020 Financial Results and Positive Progress Towards Completing the BLA Submission for VicineumTM in December 2020
Manufacturing of Vicineum drug substance and drug product PPQ batches has been completed Emerging manufacturing data provides strong support for analytical comparability between clinical and commercial material On track to complete BLA submission to the FDA in December 2020 CAMBRIDGE, Mass.
Nov 2, 2020 Sesen Bio to Host Conference Call to Review Third Quarter Financial Results and Provide an Update on Positive Progress Towards Demonstration of Analytical Comparability
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 2, 2020-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Company management will host a conference call on Monday, November 9, 2020 at
Oct 26, 2020 Sesen Bio Announces Successful Pre-Submission Meeting with the European Medicines Agency for Vicineum™
Meeting outcome confirms the Company’s pathway to a planned MAA submission for Vicineum in early 2021 with anticipated approval in early 2022 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 26, 2020-- Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics
Oct 19, 2020 Sesen Bio Announces an Exclusive Agreement With Cardinal Health for Third-Party Logistics and Specialty Pharmaceutical Distribution Services for Vicineum™
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 19, 2020-- Sesen Bio (Nasdaq:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that the Company has selected Cardinal Health as its exclusive provider for
Sep 8, 2020 Sesen Bio to Provide Business Update at the H. C. Wainwright 22nd Annual Global Investment Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 8, 2020-- Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced it will be featured as a presenting company at the H. C.
Aug 10, 2020 Sesen Bio Reports Second Quarter 2020 Financial Results and Business Update
On-track to complete BLA submission in the US in the fourth quarter of 2020 Entered into a license agreement with Qilu Pharmaceutical for the development and commercialization of Vicineum™ in Greater China with $12M upfront payment Manufacturing of PPQ campaign drug substance batches has been
Aug 5, 2020 Sesen Bio to Present Regulatory and Business Development Update at the Canaccord Genuity 40th Annual Growth Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 5, 2020-- August 5, 2020 – Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced it will be featured as a presenting company at the Canaccord Genuity
Jul 31, 2020 Sesen Bio announces an exclusive license agreement with Qilu Pharmaceutical for the development and commercialization of Vicineum™ in Greater China
Sesen to receive $12 million upfront and $23 million in potential regulatory and tech transfer milestone payments Sesen eligible to receive royalties on net sales in China Sesen to host conference call Friday, July 31 st at 8:00 a.m. EDT CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul.
Jul 30, 2020 Sesen Bio to Host Conference Call to Provide OUS Business Update
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 30, 2020-- Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Company management will host a conference call and webcast on Friday, July 31,
Displaying 1 - 10 of 18
Top